In lung cancer, the combined approach that involves HSF-1 knockdown and HSP90 inhibitor NVP-AUY922 inhibits the expression and activation of HSP90 client protein Akt and impairs Rad51-mediated homologous recombination [137] (Table 2). Here, HSF1 is linked to lung carcinoma.